Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Q3 2018 Earnings Presentation
22 slides from Precigen's earnings presentation, Nov 8, 2018
Slide 1: Third Quarter 2018 Business Update
Third Quarter 2018 Business Update November 8, 2018 Exhibit 99.2
Slide 2: Forward Looking Statements Safe Harbor Statement
Forward Looking Statements Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward
Slide 3: Intrexon and Engineered Biology
intrexon and Engineered Biology Engineered biology: The largest industrial revolution the planet has ever seen and we are a technological leader in the field Unique toolbox two decades in the making: Our precision engineering capabilities allow for controllable, multi-genic payload capacity of our g
Slide 4: Leveraging Microbes for Industrial and Therapeutic Applications
Leveraging Microbes for Industrial and Therapeutic Applications Methane Bioconversion Platform (MBP) to produce high-value fuels and chemicals Yeast fermentation platform for production of compounds for medical use
Slide 5: Proprietary genetic toolbox for Methane Bioconversion Platform
Over past several years intrexon has built a proprietary genetic toolbox for MBP to unlock its potential in methane bioconversion The cost-effective transformation of methane to higher value chemicals and fuels through fermentation is central to our fuels, lubricants and chemicals initiatives intrex
Slide 6: Intrexon's MBP – Advancing Toward Large Industrial Markets
Source: IHS Chemical, ICIS, Markets and Markets, MicroMarket Monitor, Grandview Research, Transparency Market Research Currently limited to $80bn by regulations, IEA World Outlook 2016 data ; IEA World Energy Outlook 2016 data ; Market size for 1-butene and isobutene, the main applications for butyl
Slide 7: Producing BDO from natural gas at roughly 50% of target yield
Producing BDO from natural gas at roughly 50% of the theoretical final target yield Demonstrated performance at 500X scale-up Sustained production runs exceeding 1,000 hours without reduction in output Q3 Advances © 2018 Intrexon Corp. All rights reserved.
Slide 8: Robust Microbial Production of Cannabinoids for Medical Use
Robust Microbial Production of Cannabinoids for Medical Use North American Cannabis market estimated to be $47.3 billion by 2027 Volume and market will demand production routes beyond current plant-based methods intrexon’s proprietary yeast strains enable a transformative process for robust producti
Slide 9: Bioengineering Cells for Human Gene and Cellular Therapies
Bioengineering Cells for Human Gene and Cellular Therapies Next generation targeted, controllable, multigenic therapeutic treatments across broad range of diseases Microbe-based delivery of biopharmaceuticals
Slide 10: Precigen's Multigenic Candidate Improves T Cell Activation and Anti-Tumor Response
Enhanced T-cell activation in vitro and anti-tumor response in mice upon treatment with Precigen’s multigenic candidate. Precigen’s Multigenic Candidate Provides Improved T Cell Activation and Anti-Tumor Response Compared to Approved Anti-PD-1 Checkpoint Inhibitor 2000 1750 1500 1250 1000 750 500 Ne
Slide 11: ActoBiotics – Microbe-based Biopharmaceuticals
ActoBiotics® – Microbe-based Biopharmaceuticals for Expression and Local Delivery of Therapeutics at Disease Sites Harnessing L. lactis Yields New Opportunities
Slide 12: ActoBio Updates
ActoBio Updates Oragenics, Inc. continues to enroll patients in the Phase IIb trial for AG013 in the treatment for Oral Mucositis ActoBio has dosed the first patient in the AG019 Ib/IIa trial in the treatment of early onset Type 1 Diabetes AG017, an immune tolerance approach, for the treatment of Ce
Slide 13: Engineering Biology for Food, Agriculture, Environmental, and Health Solutions
Engineering Biology for Food, Agriculture, Environmental, and Health Solutions Okanagan Specialty Fruits Trans Ova elite bovine genetics Exemplar MiniSwine research models EnviroFlight black soldier fly larvae for animal feed AquaBounty land-based salmon production
Slide 14: Scaling Arctic Apple Plantings to Meet Consumer Demand
The 2018 harvest is complete yielding 2,100 bins, 10 times more than the 2017 harvest Targeting >500 retail outlets for our fresh sliced, whole apples and ApBitz™ snacks Consumer reception to the apples has been highly favorable Expected to plant ~1,000,000 trees in the spring of 2019; additional to
Slide 15: Trans Ova and Exemplar Q3 Updates
Trans Ova Genetics Sales of embryos with elite genetics continue to a growing number of customers domestically and abroad Created six bull calves that rank at the top of the global Holstein bull population Exemplar Genetics Demand for the MiniSwine Models continues to grow Expansion into regenerativ
Slide 16: Black Soldier Fly Larvae Commercial Facility to be Operational in Q4
Ongoing construction in Maysville facility Black Soldier Fly Larvae Commercial Facility to be Operational in Q4 Advancing on schedule toward opening the largest black soldier fly larvae facility in the US in Q4 2018 Modular facility – Phase one will have the ability to produce 900mt of product a yea
Slide 17: Sustainable AquAdvantage Salmon Update
Currently distributed throughout Canada November 19, 2015 – FDA approval for production, sale, and consumption in the U.S. April 27, 2018 – FDA approval to raise AquAdvantage® Salmon at land-based Indiana facility; conventional salmon is currently being raised at the facility AquaBounty granted a CA
Slide 18: Innovations in Plant Biology and Vector Control
Innovations in Plant Biology and Vector Control
Slide 19: The Botticelli Advantage
The Botticelli™ Advantage Advanced tissue culture technology that offers a sustainable, scalable, and more economical solution for growers to meet the rapidly expanding demand for premium quality products Indefinite replication of genetics and consistent product performance with “clean” plants Impro
Slide 20: Next Gen Tissue Culture Technology
Next Gen Tissue Culture Technology Starting Tissue Proprietary Culture Method Multiple Varietal Production Lettuce Tomato
Slide 21: Oxitec – Progressing Programs for Friendly Mosquitoes
Second Collaborative Agreement with the Bill & Melinda Gates Foundation Grant to develop Friendly™ Anopheles stephensi strain is being designed to combat malaria in India, Middle East and Horn of Africa Continue to Advance Oxitec’s Second Generation Aedes Technology Ongoing transition to 5034 in US,
Slide 22: ‘ All rights reserved.
‘©2018 intrexon Corp. All rights reserved.